ASCO: Cabozantinib and Atezolizumab in Urothelial Cancer
Interview by Nazli Dizman MD Interview with Sumanta Kumar Pal MD
Related Articles
Tumor and Peritoneum-Associated Macrophage Gene Signature as a Novel Molecular Biomarker in Gastric Cancer
A spectrum of immune states resulting from tumor resident macrophages and T-lymphocytes in the solid tumor microenvironment correlates with patient outcomes. We hypothesized that in…
A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1
Abstract. Background: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors radically changed the treatment paradigm for breast cancer. Similar to estrogen receptor in breast cancer, androgen…
MOASC 2024 Oncology Summit Archives
… The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set a benchmark in oncology, providing … … At the MOASC…
MOASC 2024 Oncology Summit Archives
… The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set a benchmark in oncology, providing … … At the MOASC…
Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease
Nature Microbiology – Graft-versus-host disease, a T cell-driven inflammatory condition, is associated with altered microbial bile acid metabolism in both mice and humans and this…
Hoarseness and Wheezing in Patient With Arrhythmia
She first noticed crackling of her voice, which was worse when she laughed.
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
Nature Medicine – In the final report of a phase 1/2 trial evaluating allogeneic CD19-specific CAR-NK cells armored with IL-15 in patients with CD19+ hematologic…
Chromosomal fragile site breakage by EBV-encoded EBNA1 at clustered repeats – Nature
Epstein–Barr Virus (EBV) nuclear antigen 1 is shown to induce breakage of a fragile site on chromosome 11 by binding to a cluster of EBV-like imperfect palindromic…
FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable non-sm
On October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab…
The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023